Retatrutide vs CagriSema: Two Very Different Roads to the Same Goal
If you’ve been following the next-generation obesity-drug race and trying to keep retatrutide and CagriSema straight, the most important thing to understand is that they are very different drugs taking very different mechanism paths to the same goal. Retatrutide is a single triple-agonist molecule from Eli Lilly. CagriSema is a fixed-dose combination of two molecules — cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) — from Novo Nordisk. They are competing for the same market but they are not the same kind of drug.
Retatrutide is an investigational single-molecule triple agonist (GLP-1, GIP, glucagon) developed by Eli Lilly. As of May 2026 it is in Phase 3 trials and not yet approved.
CagriSema is a once-weekly combination injection of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 agonist) developed by Novo Nordisk. Novo Nordisk submitted a U.S. New Drug Application for CagriSema in December 2025, with REDEFINE-1 reporting a mean 20.4% to 22.7% body-weight reduction at 68 weeks depending on the analysis estimand.
Both drugs target deep weight loss in adults with obesity. They use entirely different mechanism strategies to get there, are made by competing companies, and are at different points on the regulatory timeline.
What CagriSema Actually Is
CagriSema is a once-weekly fixed-dose combination of two molecules administered together as a single subcutaneous injection.
Cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin from the pancreatic beta cells. Amylin slows gastric emptying, reduces post-meal glucose excursions, and contributes to satiety through a mechanism distinct from GLP-1. Cagrilintide alone produces meaningful weight loss in the 11% to 12% range over 68 weeks of treatment.
Semaglutide is the GLP-1 receptor agonist sold individually as Ozempic (T2D) and Wegovy (obesity). On its own in obesity, semaglutide produces approximately 15% to 16% body-weight reduction at the highest dose over 68 weeks.
Combined, the two molecules produce additive (and possibly synergistic) effects on weight loss. CagriSema is the first injectable combination of an amylin analogue and a GLP-1 agonist designed for chronic weight management.
How Their Mechanisms Differ
Retatrutide and CagriSema both produce deep weight loss, but they get there through different combinations of receptor activation.
Retatrutide. Single molecule. Activates GLP-1, GIP, and glucagon receptors. Triple agonism in one drug.
CagriSema. Two molecules. Cagrilintide activates the amylin receptor pathway. Semaglutide activates the GLP-1 receptor. The amylin and GLP-1 receptor pathways are biologically distinct but functionally complementary on appetite regulation and gastric emptying.
Notable: neither retatrutide nor CagriSema activates only the GLP-1 receptor in isolation. Both represent the next step beyond single-receptor GLP-1 agonism. They diverge in which additional pathways they engage — receptor-level diversification (retatrutide adding GIP and glucagon) versus pathway-level diversification (CagriSema adding amylin).
How the Data Compares
Both drugs have produced strong Phase 3 weight-loss results, but cross-trial comparisons require care.
CagriSema in adults with obesity (REDEFINE-1, 68 weeks): mean 20.4% body-weight reduction in the efficacy estimand analysis (vs. 3.0% on placebo), and 22.7% in the analysis assuming all participants adhered to treatment. 60% of CagriSema participants achieved at least 20% body-weight reduction. 23% achieved at least 30%.
CagriSema in adults with type 2 diabetes (REDEFINE-2, 68 weeks): mean 13.7% body-weight reduction. 73.5% of participants reached an A1C of 6.5% or lower.
Retatrutide in adults with obesity and knee osteoarthritis (TRIUMPH-4, 68 weeks): mean 28.7% body-weight reduction at the highest dose. Retatrutide in adults with type 2 diabetes (TRANSCEND-T2D-1, 40 weeks): A1C reduction of 1.7 to 2.0 percentage points, mean 16.8% body-weight reduction at the highest dose.
On weight loss specifically, retatrutide’s TRIUMPH-4 result (28.7%) exceeds CagriSema’s REDEFINE-1 result (20.4% to 22.7%). The strong caveat: TRIUMPH-4 was in adults with knee osteoarthritis, while REDEFINE-1 was in a broader obesity population. Direct head-to-head data does not exist between the two drugs.
Where They Sit on the Regulatory Timeline
CagriSema is ahead of retatrutide on the U.S. approval timeline. Novo Nordisk submitted a New Drug Application to the FDA in December 2025. Standard FDA review typically takes 10 to 12 months, which would imply a potential approval decision in late 2026.
Retatrutide has not yet been filed. Eli Lilly has publicly committed to a 2026 NDA submission, anchored by TRIUMPH-1 and TRIUMPH-2 data. Standard FDA review would imply an approval decision in 2027.
The implication: in the most optimistic timeline scenarios, CagriSema reaches the U.S. market about a year ahead of retatrutide. The first-mover advantage matters somewhat for clinical-guideline integration and payer formulary positioning, though chronic-medication markets typically rebalance over time as new options become available. For the broader picture, see our retatrutide approval updates page.
Tolerability and Side-Effect Comparison
Both drugs produce side effects typical of incretin-based therapies, with some pattern differences worth noting.
CagriSema in REDEFINE-1: gastrointestinal adverse events were reported in 72.5% of CagriSema participants vs. 34.4% on placebo. Most events were transient and mild-to-moderate in severity. Discontinuation rates due to GI events were modest.
Retatrutide in TRIUMPH-4: nausea (38.1% to 43.2%), diarrhea (33.1% to 34.7%), constipation (21.8% to 25.0%), vomiting (~20%) at the two retatrutide doses tested. Adverse-event-related discontinuations in retatrutide trials have been in the 2.2% to 5.1% range across various studies.
The pattern is broadly similar — both drugs concentrate adverse events during dose escalation, both produce a profile within the GLP-1-class expectation. Direct head-to-head comparison would require an active-comparator trial, which does not exist. For broader background on retatrutide’s tolerability profile, see our retatrutide side effects page and the safety and tolerability research summary.
Different Companies, Different Strategies
Beyond the molecules themselves, the broader corporate strategies behind each drug shape how they will compete.
Eli Lilly is pursuing a portfolio approach with multiple incretin assets at different mechanism complexities and delivery formats: tirzepatide (approved), retatrutide (Phase 3), orforglipron (Phase 3, oral). Retatrutide sits at the deep-weight-loss end of that spectrum, while orforglipron sits at the broad-access end.
Novo Nordisk is pursuing a focused leadership position in GLP-1, with semaglutide as the cornerstone and CagriSema as the next-generation extension. The amylin-combination strategy lets Novo extend semaglutide’s franchise without replacing it — a defensive design as much as an offensive one. Novo also has its own next-generation programs in development, including amycretin and other combination strategies.
From the patient perspective, what matters is that two different research strategies are converging on similar weight-loss outcomes through different mechanism paths. That convergence is itself meaningful — it suggests the obesity-medicine field is approaching a clinical effect ceiling that multiple drug-development approaches can reach. Whether retatrutide’s depth advantage holds up in head-to-head data, and whether CagriSema’s regulatory lead translates into durable market positioning, will be tested over the next two to three years.
Which Is ‘Better’?
There isn’t a single answer.
On maximum weight loss in trials so far, the data favors retatrutide.
On regulatory timeline to U.S. availability, the data favors CagriSema.
On mechanism elegance (single molecule vs combination), retatrutide is structurally simpler.
On mechanism diversity (amylin pathway in addition to GLP-1), CagriSema engages a pathway retatrutide does not.
On commercial dynamics, both will compete with each other and with the existing tirzepatide and semaglutide franchises in a market that is rapidly expanding.
The question ‘which is better’ is probably less useful than ‘which fits which patient.’ That clinical decision will only become tractable after both drugs are approved, prescribed at scale, and characterized in real-world populations beyond the trial cohorts. For broader context, see our overview of retatrutide and the future of obesity medicine.
Stay Updated
Want a single, plain-English summary when retatrutide is approved — and how it compares with CagriSema and the rest of the next-generation obesity-drug field at that point? Join our retatrutide updates list. One email per major milestone, no marketing.
Disclaimer
Retatrutide is an investigational medication. CagriSema has been filed with the FDA but is not yet approved as of May 2026. Neither drug is currently commercially available. This post is educational and should not be interpreted as medical advice or as a recommendation for any specific treatment. For information about how our content is sourced and reviewed, see our editorial policy and medical review policy.
FAQ SECTION
Is CagriSema FDA-approved?
Not as of May 2026. Novo Nordisk submitted a New Drug Application for CagriSema to the FDA in December 2025. Standard FDA review takes 10 to 12 months, which would imply a potential approval decision in late 2026. Approval is likely but not guaranteed and depends on the FDA’s review of the full data package.
How does cagrilintide work?
Cagrilintide is a long-acting synthetic analogue of the natural hormone amylin. Amylin is co-secreted with insulin from pancreatic beta cells in response to meals. It slows gastric emptying, reduces post-meal glucose spikes, and contributes to satiety through brain pathways distinct from GLP-1. Cagrilintide produces meaningful weight loss on its own (about 11–12% over 68 weeks) and adds to semaglutide’s effect when combined as CagriSema.
Can retatrutide and CagriSema be combined?
There is no clinical trial program testing this combination, and combining incretin-based therapies is generally not standard practice. Both drugs activate the GLP-1 receptor (CagriSema via semaglutide, retatrutide directly), and combining them would risk amplifying gastrointestinal side effects without clearly additive benefit. Treatment decisions should be made by the prescribing clinician on an individual basis.
Did CagriSema hit its 25% weight-loss target?
Reporting on this varies by analysis estimand. REDEFINE-1’s primary analysis showed a mean 20.4% body-weight reduction in CagriSema participants. The treatment-policy estimand showed 22.7%. Some early commentary characterized this as falling short of an aspirational 25% target. Whether 22.7% counts as a clinically transformative result is a matter of clinical judgment, not statistical interpretation.
Will retatrutide replace CagriSema?
Probably not, even if both are approved. Retatrutide and CagriSema are likely to coexist in the market, with clinical decisions between them turning on individual patient factors: weight-loss target, comorbidity profile, response to prior incretin therapies, side-effect tolerance, and payer coverage. Both will compete with tirzepatide-based products as well. Chronic-medication markets typically support multiple options rather than consolidating around a single winner.
